PCAT29

Gene basic information

symbol PCAT29
name prostate cancer associated transcript 29 (non-protein coding)
location 15q23
alias_symbol
alias_name
Tissueprostate,
Cancerprostate cancer,


Description

LncRNA PCAT29 is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and up-regulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increases proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression confers the opposite effect and suppresses growth and metastases of prostate tumors. Finally, in prostate cancer patient specimens, low PCAT29 expression correlates with poor prognostic outcomes (1).


Cancer related information

download as excel csv txt

LncRNA tissue cancer type expression level oncogene/suppress gene pathway binding gene/factor associated gene/factor proliferation apoptosis migration EMT invasion metastasis prognosis tag PMID
0 PCAT29 prostate prostate cancer / TS androgen receptor - - + hormonal resistance 25030374

Expression profile

adipose adrenal brain breast colon heart kidney leukocyte liver lung lymph node ovary prostate skeletal muscle testis thyroid tissue 0.000 0.025 0.050 0.075 0.100 0.125 0.150 0.175 0.200 fpkm 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 PCAT29

Expression profile in human body map

TCGA-BLCA TCGA-BRCA TCGA-CESC TCGA-HNSC TCGA-KICH TCGA-KIRC TCGA-KIRP TCGA-LIHC TCGA-LUAD TCGA-LUSC TCGA-PRAD TCGA-STAD TCGA-THCA TCGA-UCEC tissue 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 fpkm PCAT29 type normal tumor

Expression profile in TCGA


Genomic feature visualization


Sequence

External link



Literature

[1]. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, et al. (2014). The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res 12(8): 1081-7. link pubmed



© Bioinformatics Group of XTBG